<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968214</url>
  </required_header>
  <id_info>
    <org_study_id>NCCTG-TBCI-MA.27A</org_study_id>
    <secondary_id>NCCTG-TBCI-MA.27A</secondary_id>
    <secondary_id>CDR0000600225</secondary_id>
    <secondary_id>NCI-2009-00694</secondary_id>
    <nct_id>NCT00968214</nct_id>
  </id_info>
  <brief_title>Study of Tumor and Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled on Clinical Trial CAN-NCIC-MA27</brief_title>
  <official_title>A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the&#xD;
      laboratory may help doctors learn more about changes that occur in DNA and identify&#xD;
      biomarkers related to cancer. It may also help doctors predict how patients will respond to&#xD;
      treatment.&#xD;
&#xD;
      PURPOSE: This research study is looking at tumor and blood samples from postmenopausal women&#xD;
      with primary breast cancer enrolled on clinical trial CAN-NCIC-MA27.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To identify genetic variation, as measured by single nucleotide polymorphisms, that is&#xD;
           associated with musculoskeletal adverse events in specimens from postmenopausal women&#xD;
           with hormone receptor-positive primary breast cancer receiving adjuvant aromatase&#xD;
           inhibitors and enrolled on clinical trial CAN-NCIC-MA27.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      DNA from tumor tissue and blood specimens that have been previously collected from patients&#xD;
      are analyzed for single nucleotide polymorphisms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2008</start_date>
  <completion_date type="Actual">September 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic variation associated with musculoskeletal adverse events</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">364</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <description>DNA from blood specimens that have been previously collected from patients are analyzed for single nucleotide polymorphisms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Single group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants in the MA.27 clinical trial who received either anastrozole or exemestane for&#xD;
        adjuvant therapy of resected early breast cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer&#xD;
&#xD;
               -  Complete resection of primary tumor&#xD;
&#xD;
               -  Stage I-III (T1-3, N0-3, M0) disease&#xD;
&#xD;
          -  Enrolled in clinical trial CAN-NCIC-MA27.&#xD;
&#xD;
          -  No locally recurrent or metastatic breast cancer&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- or progesterone receptor-positive disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal status, defined as one of the following:&#xD;
&#xD;
               -  At least 60 years old&#xD;
&#xD;
               -  Age 45-59 years with spontaneous cessation of menses for &gt; 12 months prior to&#xD;
                  chemotherapy or study randomization&#xD;
&#xD;
               -  Age 45-59 years with cessation of menses for &lt; 12 months or secondary to&#xD;
                  hysterectomy AND a follicle-stimulating hormone (FSH) level in the postmenopausal&#xD;
                  range (or &gt; 34.4 IU/L)&#xD;
&#xD;
               -  Age 45-59 years on hormone replacement therapy (HRT) and discontinued HRT at&#xD;
                  diagnosis of breast cancer AND FSH level in the postmenopausal range (or &gt; 34.4&#xD;
                  IU/L)&#xD;
&#xD;
               -  Bilateral oophorectomy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Ingle, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

